Alteplase - Biologic Drug Details

✉ Email this page to a colleague

Summary for alteplase

Tradenames:	2
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for alteplase

Recent Clinical Trials for alteplase

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
The First Affiliated Hospital of Nanchang University	PHASE3
The First Affiliated Hospital of Hainan Medical College	PHASE3
Xinqiao Hospital of Chongqing	PHASE3

See all alteplase clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for alteplase Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for alteplase Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for alteplase Derived from Patent Text Search

No patents found based on company disclosures

Alteplase Market Dynamics and Financial Trajectory

Last updated: February 12, 2026

Alteplase (brand name: Activase), a recombinant tissue plasminogen activator (rtPA), remains a key agent for thrombolytic therapy. Its market relevance spans acute ischemic stroke, myocardial infarction, and pulmonary embolism. Analyzing market drivers, competitive landscape, regulatory factors, and financial outlook reveals nuanced trends shaping its trajectory.

What Are the Key Market Drivers for Alteplase?

Medical Demand

Alteplase's primary use in acute ischemic stroke, approved by FDA in 1996, continues to sustain patient volume. The American Heart Association reports over 795,000 strokes annually in the U.S., with approximately 87% ischemic strokes. Timely thrombolytic therapy remains the only effective intervention within a narrow treatment window (3-4.5 hours post-onset).

Market Expansion

Use in myocardial infarction, particularly ST-elevation MI, persists driven by guideline endorsements. There has been limited growth in new indications but a consistent need for established protocols.

Healthcare Infrastructure

Improvements in emergency response systems and stroke awareness campaigns expand access to alteplase administration, increasing usage rates. However, the narrow treatment window constrains widespread application.

Competitive Alternatives

The emergence of tenecteplase and other fibrin-specific agents has slightly impacted alteplase's market share. Nonetheless, FDA approval of generics maintains price stability.

How Does the Competitive Landscape Affect Alteplase?

Generic and Biosimilar Entry

Since 2017, several biosimilars have entered markets in regions like Europe, China, and India. In the U.S., the first biosimilar approvals occurred in 2017-2018 but face patent litigation delays.

Patent and Regulatory Environment

Alteplase's patent expired in 2002, yet exclusivity in some regions persists due to formulation patents, delaying biosimilar market entry.

Pricing Trends

Generic and biosimilar entries exert downward pressure on price. In Europe, prices for biosimilars are approximately 20–30% lower than branded versions. Such reductions impact company revenues but expand accessibility.

What Are the Regulatory Factors and Their Financial Impacts?

FDA Approvals

FDA mandates rigorous clinical trials for new indications, but for existing thrombolytic use, the focus remains on safety and efficacy. The approval process for biosimilars in the U.S. relies on the Biologics Price Competition and Innovation Act (BPCIA, 2009).

Reimbursement Policies

Centers for Medicare & Medicaid Services (CMS) reimbursement codes influence revenue. A shift toward value-based payment models favors therapies that demonstrate improved outcomes, which may limit high-cost use.

Legal and Patent Litigation

Patent disputes can delay biosimilar introduction, impacting revenue projections. Companies actively litigate to extend exclusivity periods.

What Is the Financial Trajectory for Alteplase?

Market Size and Revenue

The global thrombolytic drugs market, valued at approximately USD 1.2 billion in 2021, is projected to grow at a compound annual growth rate (CAGR) of 4-5% through 2028. Alteplase holds over 70% of this market share, driven by its established role in stroke and myocardial infarction.

Revenue Trends

In 2022, the U.S. revenue for brand alteplase approximated USD 600 million. Biosimilar competition in Europe and emerging markets could reduce average selling prices (ASPs) by 15–25%, impacting margins.

R&D and Pipeline Dynamics

Limited pipeline innovations aim to improve thrombolytic efficacy or safety. Companies investing in adjunct therapies and delivery systems seek to extend market relevance.

Impact of Price and Volume

Price reductions through biosimilars are balanced by volume increases resulting from expanded indications and access. Overall revenues are expected to plateau in mature markets, with growth driven by emerging regions.

Investment Outlook

Pharmaceutical companies may focus on pipeline diversification or combination therapies. Investment in biosimilars presents opportunities and risks; approval delays or market acceptance influence financial outcomes.

Summary of Market and Financial Outlook

Aspect	Current Status	Future Outlook
Market Size	USD 1.2 billion (2021)	CAGR of 4–5% through 2028
Revenue in U.S.	≈ USD 600 million (2022)	Stable with marginal growth; impacted by biosimilars
Biosimilar Impact	Entry in Europe and Asia	Price reductions; potential in U.S. if approval occurs
Patent Status	Expired 2002; ongoing litigations	Biosimilar market expansion
R&D Pipeline	Limited, focusing on safety and adjuncts	Marginal; competitive landscape remains stable

Key Takeaways

The alteplase market sustains demand due to its efficacy in stroke and MI.
Pricing pressure from biosimilars is likely to reduce revenue margins.
Market expansion hinges on improved access and new regional approvals.
Regulatory and patent landscapes influence biosimilar competition.
Financial growth is projected to stabilize in mature markets, with growth in emerging economies.

FAQs

1. How significant is biosimilar competition for alteplase?
Biosimilars pose a price competition threat primarily in Europe and emerging markets. Their impact in the U.S. remains limited due to patent litigations and regulatory delays.

2. What regions show the most growth potential for alteplase?
Emerging markets, especially Asia and Latin America, have increased access and expanding healthcare infrastructure, offering growth opportunities.

3. Can new indications revive alteplase's market?
Potential new indications or new delivery systems could extend its use; however, current approvals focus on established thrombolytic applications.

4. How does price regulation affect revenue prospects?
Price controls in certain countries could pressure margins; however, high-cost reimbursement schemes in developed markets sustain revenue levels.

5. What is the outlook for innovation in thrombolytic therapy?
Limited pipelines focus on safety and adjunct therapies rather than new thrombolytics, consolidating alteplase’s position unless significant breakthroughs occur.

References

American Heart Association. (2022). Heart Disease and Stroke Statistics.
MarketWatch. (2022). Global Thrombolytic Drugs Market.
FDA. (2022). Biologics Price Competition and Innovation Act.
Epocrates. (2023). Alteplase indications and usage.
WHO. (2021). Global Health Library.

More… ↓

⤷ Start Trial